A whistleblower lawsuit that a diagnostic drug, myoview, for cardiology tests was misused contrary to FDA guidelines has been settled for $30 million.  The suit was filed by a Detroit-area drug rep, James Wagel, who sold a competing product, cardiolite, but learned that myoview was being diluted and misused repeatedly, contrary to directions from the FDA. As a result of the dilution and misuse, providers were able to bill Medicare repeatedly for one container/vial of myoview.  Wagel filed his suit under the federal False Claims Act, and he will receive $5.1 million of the settlement.

Source:  USA Today

Lexington, Kentucky whistleblower lawyer Robert Abell represents whistleblowers in suits under the federal False Claims Act.

Post A Comment